Cardiovascular disease in survivors of childhood cancer

Neha Bansal; Shahnawaz M. Amdani; Kelley K. Hutchins; Steven E. Lipshultz

doi:10.1097/MOP.0000000000000675

Cardiovascular disease in survivors of childhood cancer

Neha Bansal, Shahnawaz M. Amdani, Kelley K. Hutchins, Steven E. Lipshultz

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

Original language	English (US)
Pages (from-to)	628-638
Number of pages	11
Journal	Current Opinion in Pediatrics
Volume	30
Issue number	5
DOIs	https://doi.org/10.1097/MOP.0000000000000675
State	Published - Jan 1 2018
Externally published	Yes

Keywords

Anthracycline
Cardio-oncology
Cardiotoxicity
Childhood cancer
Survivorship

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1097/MOP.0000000000000675

Fingerprint Dive into the research topics of 'Cardiovascular disease in survivors of childhood cancer'. Together they form a unique fingerprint.

Cite this

@article{383775809c0f430a924eaa56d81f4a4a,

title = "Cardiovascular disease in survivors of childhood cancer",

abstract = "A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.",

keywords = "Anthracycline, Cardio-oncology, Cardiotoxicity, Childhood cancer, Survivorship",

author = "Neha Bansal and Amdani, {Shahnawaz M.} and Hutchins, {Kelley K.} and Lipshultz, {Steven E.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1097/MOP.0000000000000675",

language = "English (US)",

volume = "30",

pages = "628--638",

journal = "Current Opinion in Pediatrics",

issn = "1040-8703",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Cardiovascular disease in survivors of childhood cancer

AU - Bansal, Neha

AU - Amdani, Shahnawaz M.

AU - Hutchins, Kelley K.

AU - Lipshultz, Steven E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

AB - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

KW - Anthracycline

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Childhood cancer

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85056496846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056496846&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000675

DO - 10.1097/MOP.0000000000000675

M3 - Article

C2 - 30124579

AN - SCOPUS:85056496846

VL - 30

SP - 628

EP - 638

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 5

ER -